Neurocrine price target raised to $174 from $152 at UBS

UBS raised the firm’s price target on Neurocrine (NBIX) to $174 from $152 and keeps a Buy rating on the shares. UBS continues to see steady upside on the stock for remainder of 2025, and tells investors in a research note that for the stock to break from the recent range-bound action, consistently strong uptake on Crenessity is key. The stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24, UBS argues.